Press Releases
Tiziana Receives $3.4 Million in Non-Dilutive Funding
Jun 28, 2024
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
Jun 26, 2024
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Jun 11, 2024
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
Jun 06, 2024
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
Jun 04, 2024
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
May 30, 2024
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
May 13, 2024
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
Apr 25, 2024
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
Apr 23, 2024
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
Apr 22, 2024
Displaying 1 - 10 of 475